Long-term outcomes data shared at sso 2024 show that patients with a low-risk decisiondx®-melanoma test result were recurrence free at three years, including those who utilized the test to help guide the decision to avoid an slnb

Friendswood, texas--(business wire)---- $cstl #cstl--castle announced new data highlighting the performance of its decisiondx-melanoma test in predicting risk of sln positivity in patients with melanoma.

CSTL Ratings Summary

CSTL Quant Ranking